In vitro Susceptibility Pattern of Major Gram Negative Isolates to Selected Antimicrobial Agents

Main Article Content

Shalini Gupta
Pankaj Mandale

Abstract

Background: The choice of choosing right anti-microbial therapy in hospitals depends on the knowledge of local anti-microbial susceptibility profile. This retrospective study was conducted to assess the in vitro susceptibility pattern of different pathogen isolates to various antibiotics including Cefepime-Amikacin-Antibiotic resistant breakers (ARBs)* in various hospitals across the Jaipur City.

Methods: To characterize the antimicrobial susceptibility pattern of different isolates from various hospitals across the Jaipur City, a retrospective, observational analysis was done for antibiogram data. A total of 1201 Gram negative isolates collected during the period from January 2017 to December 2017 were included in the study. Antibiotic sensitivity testing was done in accordance with the recommendations of Clinical Laboratory Standard Institute (CLSI) guidelines.

Results: Of the total 1201 Gram negative isolates included in this study, 51.6% were from wounds and pus specimens, 40.1% were from respiratory and 8.2% from blood. P. aeruginosa (49.7%) was the most frequently isolated pathogen distantly followed by A. baumannii (21.6%), K. pneumoniae (16.6%) and E. coli (12.1%). The highest susceptibility was reported to polymyxins (100%) including Colistin and Polymyxin B, among all the tested bacteria’s and system wise. Among all the antibiotic tested, (Cefepime-Amikacin-ARBs*) sensitivity ranged for 87.9% to 52% on pathogens (E. coli, K. pneumonia, P. aeruginosa) tested from samples of skin and soft tissue, respiratory tract, blood stream, followed by Meropenem ranged for 78.4% to 55% on pathogens (E. coli, K. pneumonia, P. aeruginosa), followed by ceftazidime-tazobactam ranged for 82.7% to 58% on pathogens (E. coli, K. pneumonia, P. aeruginosa) and 22.7% sensitive for A. baumannii to Cefoperazone sulbactam. Based on pathogen type, E. coli exhibited highest overall susceptibility and the lowest was reported by A. baumannii. The susceptibility of A. baumannii ranged from 1-26% to all the tested antibiotics except polymyxins with 100% susceptibility.

Conclusions: This in vitro susceptibility data suggests that Cefepime-Amikacin-ARBs* can serve as important therapeutic option for the treatment of various resistant Gram-negative bacterial infections to relieve the excess pressure on last resort antibiotics, carbapenems and other drugs including Colistin and polymyxin B. Cefepime-Amikacin-ARBs*on the basis of antimicrobial susceptibility data can be considered as an effective therapeutic option for carbapenems in treating gram negative bacterial infections, and could be considered as a broad spectrum antibiotic sparer’s like carbapenem, colistin and Polymyxin B.

Keywords:
Cefepime-Amikacin-ARBs, meropenem, polymyxins, susceptibility, resistance.

Article Details

How to Cite
Gupta, S., & Mandale, P. (2019). In vitro Susceptibility Pattern of Major Gram Negative Isolates to Selected Antimicrobial Agents. Asian Journal of Research in Medical and Pharmaceutical Sciences, 7(2), 1-8. https://doi.org/10.9734/ajrimps/2019/v7i230117
Section
Original Research Article

References

Barriere SL. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015;16(2): 151–3.

Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: Alarm Bells are ringing. Cureus [Internet]. 2018;9(6).
Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573035/

Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006; 42(Suppl 2):S82-89.

Hamandi B, Holbrook AM, Humar A, Brunton J, Papadimitropoulos EA, Wong GG, et al. Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients. Am J Transplant. 2009;9(7):1657–65.

Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. Crit Care Med. 2010;38(8):1651–64.

Díaz-Martín A, Martínez-González ML, Ferrer R, Ortiz-Leyba C, Piacentini E, Lopez-Pueyo MJ, et al. Antibiotic prescription patterns in the empiric therapy of severe sepsis: Combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care Lond Engl. 2012;16(6):R223.

Chaudhary M, Mir MA, Ayub SG. Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: A post-marketing surveillance study. Braz J Infect Dis. 2017;21(4):408–17.

Chaudhary M, Ayub SG, Mir MA. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia. J Infect Public Health [Internet]; 2018.
[Cited 2018 May 30]
Available:https://www.jiph.org/article/S1876-0341(18)30042-X/fulltext

Nephrotoxicity Reduction by Fixed Dose Combination of Cephalosporins and Aminoglycosides in Mus musculus Mice [Internet].
[Cited 2018 Jul 9]
Available:https://scialert.net/fulltext/?doi=ajb.2009.13.21

Chaudhary M, Soni A, Dwivedi VK. Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice. Curr Clin Pharmacol. 2008;3(3):211–4.

Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. Int J Infect Dis. 2016;50:75–82.

Kaul S, Brahmadathan KN, Jagannati M, Sudarsanam TD, Pitchamuthu K, Abraham OC, et al. One year trends in the gram-negative bacterial antibiotic susceptibility patterns in a medical intensive care unit in South India. Indian J Med Microbiol. 2007;25(3):230–5.

Mythri H, Kashinath K. Nosocomial infections in patients admitted in intensive care unit of a Tertiary Health Center, India. Ann Med Health Sci Res. 2014;4(5):738–41.

Iyer V, Sewlikar S, Desai A. Healthcare acquired infection in India – A literature review. J Microbiol Immunol Infect. 2015;48(2):S182.

Kumar SG, Adithan C, Harish BN, Sujatha S, Roy G, Malini A. Antimicrobial resistance in India: A review. J Nat Sci Biol Med. 2013;4(2):286–91.

Wattal C, Goel N, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Surveillance of multidrug resistant organisms in tertiary care hospital in Delhi, India. J Assoc Physicians India. 2010;58(Suppl):32–6.

Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis. 2011;53(1):60–7.

Datta P, Gupta V, Garg S, Chander J. Phenotypic method for differentiation of carbapenemases in Enterobacteriaceae: Study from north India. Indian J Pathol Microbiol. 2012;55(3):357–60.

Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, et al. Profile of infections and outcome in high-risk febrile neutropenia: Experience from a tertiary care cancer center in India. Med Oncol Northwood Lond Engl. 2012;29(2):1354–60.

Singh R, Jain S, Chabbra R, Naithani R, Upadhyay A, Walia M. Characterization and anti-microbial susceptibility of bacterial isolates: Experience from a tertiary care cancer center in Delhi. Indian J Cancer. 2014;51(4):477–80.

A solution to combat aminoglycoside and quinolone resistant gram negative organisms. International Journal of Current Research [Internet].
[Cited 2018 Jul 9]
Available:http://www.journalcra.com/article/solution-combat-aminoglycoside-and-quinolone-resistant-gram-negative-organisms

Kulkarni, Kulkarni. Trends in antibiotic resistance among major bacterial pathogens isolated from different specimens at a tertiary care hospital in India. JAMPS. 2018;18(1):1-7.

Loho T, Dharmayanti A. Colistin: An antibiotic and its role in multiresistant gram-negative infections. Acta Medica Indones. 2015;47(2):157–68.

Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60(9):1295–303.

Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: An epidemiological and molecular study. Int J Antimicrob Agents. 2014;44(6): 500–7.